AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi
Boundless Bio’s plans to develop a new class of cancer therapies targeting DNA found outside the nucleus of malignant cells have been boosted by a $100 million fundraising
Astellas Pharma has looked outside of the box for its latest cancer drug development partnership, joining forces with Sony on a project to find new antibody-drug conjugate
AstraZeneca has looked to China for another antibody-drug conjugate (ADC) candidate for cancer, paying $55 million for rights to a preclinical candidate from Shanghai-base
Shares in ImmunityBio were in freefall today after it revealed the FDA had rejected its marketing application for Anktiva as a treatment for bladder cancer.
